<li>cobimetinib<p>modafinil will decrease the level or effect of cobimetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Avoid coadministration. Strong or moderate CYP3A inducers may decrease cobimetinib systemic exposure by &gt;80% and reduce its efficacy.</p></li><li>isocarboxazid<p>isocarboxazid increases effects of modafinil by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.</p></li><li>linezolid<p>linezolid increases effects of modafinil by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>modafinil will decrease the level or effect of ombitasvir/paritaprevir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Technivie is contraindicated with strong or moderate CYP3A4 inducers.</p></li><li>phenelzine<p>phenelzine increases effects of modafinil by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.</p></li><li>selegiline transdermal<p>selegiline transdermal increases effects of modafinil by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.</p></li><li>tranylcypromine<p>tranylcypromine increases effects of modafinil by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.</p></li>